Also from this source

You just read:

FDA Advisory Committee Recommends Against Approval of the Use of Oral Anticoagulant XARELTO® to Reduce the Risk of Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndrome

News provided by

Janssen Research & Development, LLC

Jan 16, 2014, 04:46 EST